ArticleThe Australasian journal of dermatology2025
Health Equity and Secukinumab for Severe Psoriasis in New Zealand.
Article in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND/
objectivesThe only funded indication in New Zealand between October 2018 and April 2021 for the biologic secukinumab, an interleukin-17A antibody, was severe psoriasis. This unique period of limited availability of secukinumab allowed the evaluation of who received it and health equity.
methodsAnonymised dispensing data were obtained from the New Zealand Ministry of Health and matched with the New Zealand deprivation index, ethnicity and census data.
resultsCompared to the most socio-economically deprived, the least deprived were significantly more likely to receive secukinumab, respectively, dispensing rates per 100,000 (95% confidence interval) 4.00 (3.29-4.71) and 6.56 (5.61-7.51) p < 0.0001. Compared to European ethnicity, Māori, Pacific peoples and Asian were less likely to receive secukinumab, respectively, dispensing rates per 100,000 (95% confidence interval) 6.30 (5.81-6.79), 3.27 (2.56-3.99), 3.31 (2.28-4.33), 4.33 (3.48-5.19) p < 0.0001 all groups.
conclusionsBetween October 2018 and April 2021, the data suggest that the dispensing of secukinumab was inequitable. Those having severe psoriasis and being socio-economically disadvantaged or of Māori, Pacific and Asian compared to European ethnicity, were significantly less likely to have received secukinumab. Dermatologist workforce shortages in New Zealand are likely to compound the problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.